SCHEMBL4927170

SCHEMBL4927170

Cc1ccc(-c2ccccc2O)cc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMARCA2 P51531 2/20 0.61
SMARCA4 P51532 2/20 0.61
PBRM1 Q86U86 2/20 0.61
GAA P10253 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PDK2 Q15119 1/20 0.47
KIT P10721 1/20 0.45
CKS1B P61024 2/20 0.45
SKP1 P63208 2/20 0.45
SKP2 Q13309 2/20 0.45
LMNA P02545 3/20 0.44
MAPT P10636 3/20 0.44
TSHR P16473 1/20 0.43
TERT O14746 1/20 0.43
BACE1 P56817 2/20 0.43
GPR119 Q8TDV5 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
AKT1 P31749 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4925908 0.81 TLR9 (0.49) SMARCA2SMARCA4PBRM1KITCKS1B
SCHEMBL4922449 0.79 KDM4E (0.51) SMN1; SMN2LMNAMEN1KMT2AALDH1A1
SCHEMBL2382922 0.79 GAA (0.69) SMARCA2SMARCA4PBRM1GAASMN1; SMN2
SCHEMBL30613376 0.79 GAA (0.69) SMARCA2SMARCA4PBRM1GAASMN1; SMN2
SCHEMBL3436307 0.79 AKR1C3 (0.57) SMARCA2SMARCA4PBRM1GAASMN1; SMN2
SCHEMBL20818663 0.78 CKS1B (0.58) SMARCA2SMARCA4PBRM1PDK2KIT
SCHEMBL15114426 0.77 MAPT (0.49) SMARCA2SMARCA4PBRM1LMNAMAPT
SCHEMBL116544 0.77 NR1H2 (0.54) SMARCA2SMARCA4PBRM1GAASMN1; SMN2
SCHEMBL18038763 0.76 PBRM1 (1.00) SMARCA2SMARCA4PBRM1
SCHEMBL30667399 0.76 PBRM1 (1.00) SMARCA2SMARCA4PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076338-B2 Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation EXELIXIS, INC. (US) 2011-12-13 US disclosed
US-20080076774-A1 Kinase Modulators and Methods of Use EXELIXIS, INC. (US) 2008-03-27 US disclosed
EP-1750727-A2 KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2007-02-14 EP disclosed
WO-2005117909-A2 KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076774-A1 Kinase Modulators and Methods of Use AKT3, RPS6KA3, CDK3 SMARCA2 3234/4885SMARCA4 3080/4885PBRM1 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.